Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages

Tommy Nyberg; Katie Harman; Asad Zaidi; Shaun R. Seaman; Nick Andrews; Sophie G. Nash; Andre Charlett; Jamie Lopez Bernal; Richard Myers; Natalie Groves; Eileen Gallagher; Saheer Gharbia; Meera Chand; Simon Thelwall; Daniela De Angelis; Gavin Dabrera; Anne M. Presanis

doi:10.1093/infdis/jiac063

Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages

Tommy Nyberg^*, Katie Harman, Asad Zaidi, Shaun R. Seaman, Nick Andrews, Sophie G. Nash, Andre Charlett, Jamie Lopez Bernal, Richard Myers, Natalie Groves, Eileen Gallagher, Saheer Gharbia, Meera Chand, Simon Thelwall, Daniela De Angelis, Gavin Dabrera, Anne M. Presanis

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

To investigate if the AY.4.2 sublineage of the SARS-CoV-2 delta variant is associated with hospitalization and mortality risks that differ from non-AY.4.2 delta risks, we performed a retrospective cohort study of sequencing-confirmed COVID-19 cases in England based on linkage of routine health care datasets. Using stratified Cox regression, we estimated adjusted hazard ratios (aHR) of hospital admission (aHR = 0.85; 95% confidence interval [CI],. 77-.94), hospital admission or emergency care attendance (aHR = 0.87; 95% CI,. 81-.94), and COVID-19 mortality (aHR = 0.85; 95% CI,. 71-1.03). The results indicate that the risks of hospitalization and mortality are similar or lower for AY.4.2 compared to cases with other delta sublineages.

Original language	English
Pages (from-to)	808-811
Number of pages	4
Journal	Journal of Infectious Diseases
Volume	226
Issue number	5
DOIs	https://doi.org/10.1093/infdis/jiac063
Publication status	Published - 1 Sept 2022

Bibliographical note

Funding Information:
This work was supported by the United Kingdom Research and Innovation Medical Research Council (UKRI MRC) (unit programme numbers MC_UU_00002/11 to D. D. A. and A. M. P., and MC_UU_00002/10 to S. R. S.); UKRI MRC/ Department of Health and Social Care National Institute for Health Research (NIHR) COVID-19 Rapid Response Call (grant number MC_PC_19074 to T. N., A. C., D. D. A., and A. M. P.); NIHR Health Protection Unit in Behavioural Science and Evaluation (to D. D. A.); and NIHR Cambridge Biomedical Research Centre (grant number BRC-1215-20014).

Funding Information:
Potential conflicts of interest. G. D. declares that his employer, UK Health Security Agency, previously known as Public Health England, received funding from GlaxoSmithKline for a research project related to influenza antiviral treatment. This preceded and had no relation to COVID-19, and G. D. had no role in and received no funding from the project. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press for the Infectious Diseases Society of America.

Keywords

AY.4.2
COVID-19
SARS-CoV-2
VUI-21OCT-01
hospitalization
mortality

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/infdis/jiac063

Cite this

Nyberg, T., Harman, K., Zaidi, A., Seaman, S. R., Andrews, N., Nash, S. G., Charlett, A., Lopez Bernal, J., Myers, R., Groves, N., Gallagher, E., Gharbia, S., Chand, M., Thelwall, S., De Angelis, D., Dabrera, G., & Presanis, A. M. (2022). Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages. Journal of Infectious Diseases, 226(5), 808-811. https://doi.org/10.1093/infdis/jiac063

@article{12ca37f5306c439f95752881b36b4588,

title = "Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages",

abstract = "To investigate if the AY.4.2 sublineage of the SARS-CoV-2 delta variant is associated with hospitalization and mortality risks that differ from non-AY.4.2 delta risks, we performed a retrospective cohort study of sequencing-confirmed COVID-19 cases in England based on linkage of routine health care datasets. Using stratified Cox regression, we estimated adjusted hazard ratios (aHR) of hospital admission (aHR = 0.85; 95% confidence interval [CI],. 77-.94), hospital admission or emergency care attendance (aHR = 0.87; 95% CI,. 81-.94), and COVID-19 mortality (aHR = 0.85; 95% CI,. 71-1.03). The results indicate that the risks of hospitalization and mortality are similar or lower for AY.4.2 compared to cases with other delta sublineages.",

keywords = "AY.4.2, COVID-19, SARS-CoV-2, VUI-21OCT-01, hospitalization, mortality",

author = "Tommy Nyberg and Katie Harman and Asad Zaidi and Seaman, {Shaun R.} and Nick Andrews and Nash, {Sophie G.} and Andre Charlett and {Lopez Bernal}, Jamie and Richard Myers and Natalie Groves and Eileen Gallagher and Saheer Gharbia and Meera Chand and Simon Thelwall and {De Angelis}, Daniela and Gavin Dabrera and Presanis, {Anne M.}",

note = "Funding Information: This work was supported by the United Kingdom Research and Innovation Medical Research Council (UKRI MRC) (unit programme numbers MC_UU_00002/11 to D. D. A. and A. M. P., and MC_UU_00002/10 to S. R. S.); UKRI MRC/ Department of Health and Social Care National Institute for Health Research (NIHR) COVID-19 Rapid Response Call (grant number MC_PC_19074 to T. N., A. C., D. D. A., and A. M. P.); NIHR Health Protection Unit in Behavioural Science and Evaluation (to D. D. A.); and NIHR Cambridge Biomedical Research Centre (grant number BRC-1215-20014). Funding Information: Potential conflicts of interest. G. D. declares that his employer, UK Health Security Agency, previously known as Public Health England, received funding from GlaxoSmithKline for a research project related to influenza antiviral treatment. This preceded and had no relation to COVID-19, and G. D. had no role in and received no funding from the project. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Oxford University Press for the Infectious Diseases Society of America.",

year = "2022",

month = sep,

day = "1",

doi = "10.1093/infdis/jiac063",

language = "English",

volume = "226",

pages = "808--811",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "5",

}

Nyberg, T, Harman, K, Zaidi, A, Seaman, SR, Andrews, N, Nash, SG, Charlett, A , Lopez Bernal, J, Myers, R, Groves, N, Gallagher, E, Gharbia, S , Chand, M , Thelwall, S , De Angelis, D , Dabrera, G & Presanis, AM 2022, 'Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages', Journal of Infectious Diseases, vol. 226, no. 5, pp. 808-811. https://doi.org/10.1093/infdis/jiac063

TY - JOUR

T1 - Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages

AU - Nyberg, Tommy

AU - Harman, Katie

AU - Zaidi, Asad

AU - Seaman, Shaun R.

AU - Andrews, Nick

AU - Nash, Sophie G.

AU - Charlett, Andre

AU - Lopez Bernal, Jamie

AU - Myers, Richard

AU - Groves, Natalie

AU - Gallagher, Eileen

AU - Gharbia, Saheer

AU - Chand, Meera

AU - Thelwall, Simon

AU - De Angelis, Daniela

AU - Dabrera, Gavin

AU - Presanis, Anne M.

N1 - Funding Information: This work was supported by the United Kingdom Research and Innovation Medical Research Council (UKRI MRC) (unit programme numbers MC_UU_00002/11 to D. D. A. and A. M. P., and MC_UU_00002/10 to S. R. S.); UKRI MRC/ Department of Health and Social Care National Institute for Health Research (NIHR) COVID-19 Rapid Response Call (grant number MC_PC_19074 to T. N., A. C., D. D. A., and A. M. P.); NIHR Health Protection Unit in Behavioural Science and Evaluation (to D. D. A.); and NIHR Cambridge Biomedical Research Centre (grant number BRC-1215-20014). Funding Information: Potential conflicts of interest. G. D. declares that his employer, UK Health Security Agency, previously known as Public Health England, received funding from GlaxoSmithKline for a research project related to influenza antiviral treatment. This preceded and had no relation to COVID-19, and G. D. had no role in and received no funding from the project. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Publisher Copyright: © 2022 The Author(s). Published by Oxford University Press for the Infectious Diseases Society of America.

PY - 2022/9/1

Y1 - 2022/9/1

N2 - To investigate if the AY.4.2 sublineage of the SARS-CoV-2 delta variant is associated with hospitalization and mortality risks that differ from non-AY.4.2 delta risks, we performed a retrospective cohort study of sequencing-confirmed COVID-19 cases in England based on linkage of routine health care datasets. Using stratified Cox regression, we estimated adjusted hazard ratios (aHR) of hospital admission (aHR = 0.85; 95% confidence interval [CI],. 77-.94), hospital admission or emergency care attendance (aHR = 0.87; 95% CI,. 81-.94), and COVID-19 mortality (aHR = 0.85; 95% CI,. 71-1.03). The results indicate that the risks of hospitalization and mortality are similar or lower for AY.4.2 compared to cases with other delta sublineages.

AB - To investigate if the AY.4.2 sublineage of the SARS-CoV-2 delta variant is associated with hospitalization and mortality risks that differ from non-AY.4.2 delta risks, we performed a retrospective cohort study of sequencing-confirmed COVID-19 cases in England based on linkage of routine health care datasets. Using stratified Cox regression, we estimated adjusted hazard ratios (aHR) of hospital admission (aHR = 0.85; 95% confidence interval [CI],. 77-.94), hospital admission or emergency care attendance (aHR = 0.87; 95% CI,. 81-.94), and COVID-19 mortality (aHR = 0.85; 95% CI,. 71-1.03). The results indicate that the risks of hospitalization and mortality are similar or lower for AY.4.2 compared to cases with other delta sublineages.

KW - AY.4.2

KW - COVID-19

KW - SARS-CoV-2

KW - VUI-21OCT-01

KW - hospitalization

KW - mortality

UR - http://www.scopus.com/inward/record.url?scp=85128511920&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiac063

DO - 10.1093/infdis/jiac063

M3 - Article

C2 - 35184201

AN - SCOPUS:85128511920

SN - 0022-1899

VL - 226

SP - 808

EP - 811

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 5

ER -

Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this